Scynexis Inc (SCYX)

04:42 AM

What drives SCYNEXIS Inc. stock priceUnmatched market performance - jammulinksnews.com

04:42 AM

08:34 AM

Is SCYNEXIS Inc. a good long term investmentUnprecedented market success - Autocar Professional

08:34 AM

04:28 AM

SCYNEXIS Inc. Stock Analysis and ForecastFast-track wealth growth - Autocar Professional

04:28 AM

Jul 22, 2025

What analysts say about SCYNEXIS Inc. stockAccelerated wealth building - jammulinksnews.com

Jul 22, 2025

Jul 19, 2025

Is ATH.PRA a good long term investmentSkyrocketing returns - Jammu Links News

Jul 19, 2025

Jul 16, 2025

What makes SCYNEXIS Inc. stock price move sharplyTop Analyst Picks - Newser

Jul 16, 2025

Jul 15, 2025

Why SCYNEXIS Inc. stock attracts strong analyst attentionGrowth Stock Monitor - Newser

Jul 15, 2025

Jul 15, 2025

How SCYNEXIS Inc. stock performs during market volatilityFree Stock Market Analysis Courses - Newser

Jul 15, 2025

Jul 15, 2025

Scynexis Inc (SCYX) Stock: A Year of Highs and Lows in the Market - investchronicle.com

Jul 15, 2025

Jul 02, 2025

SCYNEXIS Holds Annual Meeting, Re-elects Directors - The Globe and Mail

Jul 02, 2025

Jun 26, 2025

SCYNEXIS Faces Nasdaq Delisting Notice for Stock Price - TipRanks

Jun 26, 2025

Jun 15, 2025

Millennium Management LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

Jun 15, 2025

Jun 11, 2025

Squarepoint Ops LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

Jun 11, 2025

Jun 10, 2025

Jane Street Group LLC Buys New Holdings in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

Jun 10, 2025

Jun 06, 2025

Bright Minds Biosciences (NASDAQ:DRUG) & SCYNEXIS (NASDAQ:SCYX) Head-To-Head Survey - Defense World

Jun 06, 2025

Jun 05, 2025

Biosergen taps antifungal expert as board member - Biostock

Jun 05, 2025

Jun 03, 2025

Northern Trust Corp Has $186,000 Stake in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

Jun 03, 2025

May 29, 2025

Scynexis resumes dosing in Phase III MARIO study after lengthy delay - MSN

May 29, 2025

May 29, 2025

SCYNEXIS resumes Phase 3 antifungal study after FDA lift By Investing.com - Investing.com South Africa

May 29, 2025

May 29, 2025

SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold - Insider Monkey

May 29, 2025

May 28, 2025

Scynexis resumes patient dosing in Phase 3 MARIO study - TipRanks

May 28, 2025

May 28, 2025

SCYNEXIS Resumes Patient Dosing In Phase 3 MARIO Study - marketscreener.com

May 28, 2025

May 28, 2025

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study | SCYX St - GuruFocus

May 28, 2025

May 28, 2025

GSK Involved in SCYNEXIS's Phase 3 Study Milestone Dispute | GSK Stock News - GuruFocus

May 28, 2025

May 28, 2025

SCYNEXIS resumes Phase 3 antifungal study after FDA lift - Investing.com Australia

May 28, 2025

May 28, 2025

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study | SCYX Stock News - GuruFocus

May 28, 2025

May 28, 2025

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study - The Manila Times

May 28, 2025

May 28, 2025

SCYNEXIS Restarts Critical Phase 3 Trial for Life-Threatening Infection, Faces $30M GSK Payment Battle - Stock Titan

May 28, 2025

May 19, 2025

SCYNEXIS Faces Challenges Amidst Antifungal Developments - TipRanks

May 19, 2025

May 16, 2025

FDA lifts hold on Scynexis trial; Incyte’s Zynyz notches another FDA approval - Endpoints News

May 16, 2025

May 16, 2025

SCYNEXIS (NASDAQ:SCYX) Now Covered by Analysts at StockNews.com - Defense World

May 16, 2025

May 16, 2025

SCYNEXIS Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 16, 2025